XERS - NASDAQ
Xeris Biopharma Holdings, Inc.
$5.89
-1.8%Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
At a Glance
Live SnapshotXeris Biopharma Holdings, Inc. Management Team
Mr. John P. Shannon
Chief Executive Officer & Director
Compensation
$1,065,572
Mr. Steven M. Pieper
Chief Financial Officer
Compensation
$747,017
Ms. Beth P. Hecht J.D.
Chief Legal Officer & Corporate Secretary
Compensation
$767,825
Dr. Anh Nguyen M.B.A., M.D.
Chief Medical Officer
Mr. Kevin McCulloch
President & Chief Operating Officer
Compensation
$777,048
Mr. Brian Conner
SVice President of Quality and Chief Compliance & Risk Officer
Mr. Paul R. Edick J.D.
Senior Advisor
Compensation
$2,597,639
Ms. Kendal Korte
Senior Vice President of Human Resources
Ms. Allison Wey
Senior Vice President of Investor Relations & Corporate Communications
Xeris Biopharma Holdings, Inc. Insider Positioning
During the last 12 months, insiders have purchased $313K and sold $2.63M worth of XERS shares, resulting in $2.32M of net selling activity.
3 Months
0
0.00
60.8K
364.68K
-365K
-$365K
3-6 Months
0
0.00
240.2K
1.73M
-1.7M
-$1.73M
6-9 Months
0
0.00
72.8K
539.18K
-539K
-$539K
9-12 Months
47.0K
313.29K
0
0.00
+313K
+$313K
Top Buyers
Sherman Jeffrey W
Director
$313K
Top Sellers
Johnson John
Director
$977K
Hecht Beth
Officer: See Remarks
$896K
Shannon John Patrick Jr
Director, Officer: See Remarks
$350K
Mcculloch Kevin
Officer: See Remarks
$126K
Persky Marla
Director
$120K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $2.32M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
XERS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 23, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2025 | December 31, 2024 | 2024 | |
DEF 14A DEF 14A 2024 N/A | April 23, 2024 | June 05, 2024 | 2024 | |
DEF 14A DEF 14A 2022 N/A | April 26, 2023 | December 31, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2022 | December 31, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.